Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Cailin Conner
Articles by Cailin Conner
Pacritinib Improves Symptom Relief in Patients With Myelofibrosis Requiring RBC Transfusions
Cailin Conner
Myelofibrosis
|
October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Read More
Study Highlights Genomic, Laboratory Differences in Myelofibrosis Treated With Pacritinib Versus Momelotinib
Cailin Conner
Myelofibrosis
|
October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Read More
Study Validates Prognostic Models, Genetic Markers in Patients With Myelofibrosis
Cailin Conner
Myelofibrosis
|
October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Read More
Momelotinib, Pacritinib Exhibit Improved Outcomes, Low Discontinuation Rates in Myelofibrosis With Cytopenias
Cailin Conner
Myelofibrosis
|
October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Read More
Ibrutinib Plus Venetoclax Yields Durable PFS in CLL, SLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 20, 2024
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Read More
Study Establishes Median PFS, OS Benefits of Ibrutinib in Older Patients With CLL, SLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 20, 2024
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Read More
Oral Inhibitors Safe for CLL Patients With Severe Renal Dysfunction
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 20, 2024
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Read More
Switching Rates Lower With Zanubrutinib Versus Other BTK Inhibitors in CLL, SLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 20, 2024
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
Read More
Quizartinib Enhances Survival in FLT3-ITD+ AML With Deep MRD Reduction
Cailin Conner
Acute Myeloid Leukemia
|
September 6, 2024
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Read More
HMAs Plus Venetoclax Increases AML Survival, Requires More Resources
Cailin Conner
Acute Myeloid Leukemia
|
September 6, 2024
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
Read More
Study Links Overexpression of SLC40A1 to Poor Prognosis in AML
Cailin Conner
Acute Myeloid Leukemia
|
September 9, 2024
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Read More
Hematologic Recovery Associated With Better Survival in Pediatric AML
Cailin Conner
Acute Myeloid Leukemia
|
September 6, 2024
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
Read More
Venetoclax Plus Lenalidomide, Rituximab ‘Safe’ in Frontline MCL Treatment
Cailin Conner
Mantle Cell Lymphoma
|
October 6, 2023
The investigators conceded the longer follow-up is needed but the results are promising.
Read More
Acalabrutinib Exhibits Better Benefit-Risk Profile, Lower Cardiovascular Toxicity Versus Ibrutinib in CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 25, 2023
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Read More
Highly Complex Karyotypes, Translocations Are Adverse Prognostic Factors in Venetoclax-Based Combinations for CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 22, 2023
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Read More
Favorable Long-term PFS in Patients with CLL, Mutated IGHV Following FCR Treatment
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 25, 2023
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Read More
Tagraxofusp Granted Orphan Drug Designation to Treat BPDCN
Cailin Conner
Print
|
October 11, 2023
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Read More
Study Evaluates CLL Treatment Approaches in Turkey
Cailin Conner
Meeting News
|
September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Read More
Study Finds Comparable Outcomes of Multihit Versus Single-Hit TP53 Alterations in CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Read More
Improved Outcomes in Patients Treated with Ruxolitinib After Hydroxyurea
Cailin Conner
Meeting News
|
September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Read More
Load More